Norm-based comparison of the quality-of-life impact of ravulizumab and eculizumab in paroxysmal nocturnal hemoglobinuria

AIMS: Paroxysmal nocturnal hemoglobinuria (PNH) is a rare and life-threatening intravascular hematologic disorder with significant morbidity and premature mortality. Clinical trials (NCT02946463 and NCT03056040) comparing ravulizumab with eculizumab for PNH have supported the non-inferiority of the...

Descripción completa

Detalles Bibliográficos
Autores principales: Schwartz, Carolyn E., Stark, Roland B., Borowiec, Katrina, Nolte, Sandra, Myren, Karl-Johan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8442345/
https://www.ncbi.nlm.nih.gov/pubmed/34526067
http://dx.doi.org/10.1186/s13023-021-02016-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8442345/
https://www.ncbi.nlm.nih.gov/pubmed/34526067
http://dx.doi.org/10.1186/s13023-021-02016-8

Ejemplares similares